← 返回

沙特阿拉伯一家三级癌症中心 T 细胞淋巴瘤的真实世界结局

英文原题:Real-world outcomes of T cell lymphoma in a tertiary cancer center in Saudi Arabia.

查看英文原题

Real-world outcomes of T cell lymphoma in a tertiary cancer center in Saudi Arabia.

PubMed 2026/08/06(内容时间) Ann Saudi Med Q2 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

LDH 升高、体能状态差和肾功能不全是生存期较差的强独立预测因素。在本队列中,干细胞移植未显示出生存获益。这些发现强调了基线实验室和临床变量对风险分层的重要性,并为沙特阿拉伯的多中心研究和治疗优化提供了基础。局限性:样本量和单中心回顾性设计限制了普遍适用性。未评估治疗方案中移植相关的具体细节。

研究思路结论见上方概要

T细胞和自然杀伤(T/NK)细胞淋巴瘤是罕见且侵袭性强的恶性肿瘤。在我们的研究之前,沙特阿拉伯尚未发表过针对T/NK细胞淋巴瘤的专门机构生存分析。

评估在沙特阿拉伯一家三级癌症转诊中心接受治疗的T/NK细胞淋巴瘤患者的临床特征、预后因素和生存结局。

回顾性队列研究。沙特阿拉伯利雅得King Abdulaziz Medical City, Ministry of National Guard-Health Affairs;2016年1月至2022年12月。我们回顾了89例经组织学确诊的成人T/NK细胞淋巴瘤患者的病历,包括前体和成熟亚型。总生存期(OS)采用Kaplan-Meier法估计。预后因素采用单变量和多变量Cox比例风险回归进行评估。为保持稳健的每变量事件数比,多变量模型限制为四个预测因子。主要结局指标:5年总生存期及与死亡率相关变量的识别。样本量:89例患者。

中位年龄为49.5 20.5岁,62例患者(70%)为男性。最常见的亚型为ALK阴性间变性大细胞淋巴瘤(n=20,22%)和非特指型外周T细胞淋巴瘤(n=15,17%)。对于整个队列(N=89),5年OS为56%(95% CI,44%-67%);Kaplan-Meier估计的整个可用随访期间平均OS为116.4个月。在限于70例数据完整患者(26例死亡)的多变量分析中,乳酸脱氢酶(LDH)升高(风险比[HR]=7.66;95%置信区间[CI],1.77-33.19;P =.006)、东部肿瘤协作组(ECOG)体能状态>2(HR=4.26;95% CI,1.60-11.33;P =.004)和肾功能不全(HR=3.06;95% CI,1.34-6.97;P =.008)是生存较差的独立预测因素。贫血有生存较差的趋势,但未达到独立显著性(HR=2.30;95% CI,0.95-5.58;P =.066)。

展开英文摘要原文

T-cell and natural-killer (T/NK)-cell lymphomas are rare and aggressive malignancies. Prior to our study, no dedicated institutional survival analyses of T/NK-cell lymphomas had been published from Saudi Arabia.

To evaluate the clinical characteristics, prognostic factors, and survival outcomes of patients with T/NK-cell lymphoma treated at a tertiary cancer referral centre in Saudi Arabia. DESIGN: Retrospective cohort study. SETTING: King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia; January 2016 to December 2022.

We reviewed medical records of 89 adults with histologically confirmed T/NK-cell lymphomas, including precursor and mature subtypes. Overall survival (OS) was estimated using the Kaplan-Meier method. Prognostic factors were assessed with univariate and multivariable Cox proportional hazards regression. To maintain a robust events-per-variable ratio, the multivariable model was restricted to four predictors. MAIN OUTCOME MEASURES: Five-year overall survival and identification of variables associated with mortality. SAMPLE SIZE: 89 patients.

The mean age was 49.5 20.5 years, and 62 patients (70%) were male. The most common subtypes were ALK-negative anaplastic large-cell lymphoma (n=20, 22%) and peripheral T-cell lymphoma, not otherwise specified (n=15, 17%). For the entire cohort (N=89), the 5-year OS was 56% (95% CI, 44%-67%); the Kaplan-Meier estimated mean OS over the full available follow-up was 116.4 months. In multivariable analysis restricted to 70 patients with complete data (26 deaths), elevated lactate dehydrogenase (LDH) (hazard ratio [HR]=7.66; 95% confidence interval [CI], 1.77-33.19; P =.006), Eastern Cooperative Oncology Group (ECOG) performance status >2 (HR=4.26; 95% CI, 1.60-11.33; P =.004), and renal insufficiency (HR=3.06; 95% CI, 1.34-6.97; P =.008) were independent predictors of worse survival. Anemia trended toward worse survival but did not reach independent significance (HR=2.30; 95% CI, 0.95-5.58; P =.066).

Elevated LDH, poor performance status, and renal insufficiency are strong independent predictors of inferior survival. Stem cell transplantation did not demonstrate a survival benefit in this cohort. These findings underscore the importance of baseline laboratory and clinical variables for risk stratification and provide groundwork for multicentre studies and therapeutic optimisation in Saudi Arabia. LIMITATIONS: Sample size and single-centre retrospective design limit generalisability. Transplant-specific details in treatment regimens were not evaluated.

论文信息

作者
Alqahtani S、Assiri M、Abdu AB、Alyusif K、Alharbi M、Alharbi Z、Alsubaie A、Alhamzani A
第一作者单位
From the College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.Saudi Arabia
期刊
Annals of Saudi medicine2026 Jul-Aug
原文标识
PubMed 42571032 · DOI 10.5144/0256-4947.2026.249